Cancer is complex. Fortunately, so is your immune system. It's able to adapt and keep pace with cancer, and becomes a "living drug" that continues to work for patients long after treatment with immunotherapy has ceased. Immunotherapy has been shown to benefit patients with melanoma, lung cancer, kidney cancer, colorectal cancer, and many other kinds of cancer.
Former U.S. president Jimmy Carter is just one example of the power of immunotherapy. He was treated with an immunotherapy that is taking the brakes off his immune system's response to cancer, unleashing his natural defenses to eliminate all traces of his advanced melanoma. Thousands of patients have experienced dramatic remissions of their cancers, and some patients with previously untreatable cancer today remain cancer-free more than 10 years after treatment. Patients like Deborah, who got a second chance at life thanks to immunotherapy. Or Philip, whose colorectal cancer came back for a second time and was finally halted with immunotherapy.
Immunotherapy offers an answer to cancer for some patients. The Cancer Research Institute, which pioneered the field and is a leader today in bringing lifesaving immunotherapies to more patients, is committed to funding the research that is needed to realize immunotherapy's potential to benefit all cancer patients. From basic laboratory research to clinical trials of promising new treatments, CRI supports the entire spectrum of discovery and innovation.